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Background: Special AT-rich sequence-binding protein 1 (SATB1) is a global gene regulator that has been reported
to confer malignant behavior and associate with poor prognosis in several cancer forms. SATB1 expression has
been demonstrated to correlate with unfavourable tumour characteristics in rectal cancer, but its association with
clinical outcome in colorectal cancer (CRC) remains unclear. In this study, we examined the prognostic impact of
SATB1 expression in CRC, and its association with important molecular characteristics; i.e. beta-catenin
overexpression, microsatellite instability (MSI) screening status, and SATB2 expression.
Methods: Immunohistochemical expression of SATB1 and beta-catenin was assessed in tissue microarrays with
tumours from 529 incident CRC cases in the prospective population-based Malmö Diet and Cancer Study,
previously analysed for SATB2 expression and MSI screening status. Spearman´s Rho and Chi-Square tests were used
to explore correlations between SATB1 expression, clinicopathological and investigative parameters. Kaplan Meier
analysis and Cox proportional hazards modelling were used to explore the impact of SATB1 expression on cancer
specific survival (CSS) and overall survival (OS).
Results: SATB1 was expressed in 222 (42%) CRC cases and negative, or sparsely expressed, in adjacent colorectal
mucosa (n = 16). SATB1 expression was significantly associated with microsatellite stable tumours (p < 0.001),
beta-catenin overexpression (p < 0.001) and SATB2 expression (p < 0.001). While not prognostic in the full
cohort, SATB1 expression was significantly associated with poor prognosis in SATB2 negative tumours (HR = 2.63;
95% CI 1.46-4.71; pinteraction = 0.011 for CSS and HR= 2.31; 95% CI 1.32-4.04; pinteraction = 0.015 for OS), remaining
significant in multivariable analysis.
Conclusions: The results of this study demonstrate that SATB1 expression in CRC is significantly associated with
beta-catenin overexpression, microsatellite stability and SATB2 expression. Furthermore, SATB1 expression is a factor
of poor prognosis in SATB2 negative tumours. Altogether, these data indicate an important role for SATB1 in
colorectal carcinogenesis and suggest prognostically antagonistic effects of SATB1 and SATB2. The mechanistic
basis for these observations warrants further study.
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Colorectal cancer (CRC) is one of the most common
forms of human cancer worldwide with approximately
1 million new cases detected every year [1]. Currently,
tumour stage at diagnosis is the most important prognos-
tic factor in CRC and although many efforts have been
made to find molecular markers to identify high-risk
disease and to select patients for adjuvant treatment,
none have proven good enough for use in clinical routine.
We have previously demonstrated that special AT-rich
sequence-binding protein 2 (SATB2), a nuclear matrix
associated protein and epigenetic regulator that orches-
trates the function of multiple genes [2], is expressed
in a highly tissue-specific manner in normal mucosa of
the lower gastrointestinal tract and in CRC [3,4]. More-
over, loss of SATB2 expression has been shown to
correlate with poor prognosis in CRC [4,5].
The T-lineage enriched global chromatin organizer
SATB1 [6,7] is a close homologue to SATB2, and expres-
sion of SATB1 has been reported to correlate with poor
prognosis in several cancer forms, e.g. breast, gastric and
liver cancer [8-11]. In a recent study, mRNA and protein
levels of SATB1 were found to correlate with unfavour-
able tumour characteristics in rectal cancer, but the prog-
nostic significance of SATB1 expression was not reported
[12]. This study included 93 patients and SATB1 was
found to be up-regulated in invasive cancer compared to
normal rectal mucosa, but overexpression or positive
staining was denoted in < 50% of the tumours, indicating
that SATB1 is less abundantly expressed than SATB2 in
the lower gastrointestinal tract but may play an important
role in colorectal carcinogenesis [12]. SATB2 has also
been found to inhibit the expression of SATB1 in human
CRC cells in vitro [5]. Moreover, as activation of the
WNT signaling pathway and its major mediator beta-
catenin is a critical event in colorectal carcinogenesis [13],
and SATB1 has been shown to interact with and recruit
beta-catenin to its genomic binding sites, the role of
SATB1 in CRC development and progression merits fur-
ther investigation.
The aim of this study was therefore to examine the
extent and prognostic significance of SATB1 expression
in a large, prospective CRC cohort [14,15]. In addition,
we analysed the molecular correlates of SATB1 expres-
sion with beta-catenin overexpression, MSI screening
status and SATB2 expression.
Methods
Study group
Until end of follow-up 31 December 2008, 626 incident
cases of CRC had been registered in the prospective,
population-based cohort study Malmö Diet and Cancer
Study (MDCS) [16]. Cases were identified from the
Swedish Cancer Registry up until 31 Dec 2007, and fromThe Southern Swedish Regional Tumour Registry for the
period of 1 Jan - 31 Dec 2008. All tumours with avail-
able slides or paraffin blocks were histopathologically
re-evaluated on haematoxylin and eosin stained slides. His-
topathological, clinical and treatment data were obtained
from the clinical and/or pathology records. TNM staging
was performed according to the American Joint Com-
mittee on Cancer (AJCC). Information on vital status
and cause of death was obtained from the Swedish Cause
of Death Registry up until 31 Dec 2009. Follow-up
started at date of diagnosis and ended at death, emigra-
tion or 31 Dec 2009, whichever came first. Median
follow-up time was 3.35 years (range 0–17.69) for the full
cohort (n = 626) and 6.05 years (range 1.03-17.69) for
patients alive (n = 344). Patient and tumour characteris-
tics of the cohort have been described in detail pre-
viously [4,14,15]. Ethical permission was obtained from
the Ethics Committee at Lund University for the MDCS
(Ref. 51/90), and the present study (Ref. 530/2008).Tissue microarray construction
Cases with an insufficient amount of tumour material
were excluded, whereby a total number of 557 (89.0%)
tumours were suitable for tissue microarray (TMA) con-
struction. Areas representative of cancer were marked
on haematoxylin & eosin stained slides and TMAs were
constructed as previously described [17]. In brief, two
1.0 mm cores were taken from each tumour and mounted
in a new recipient block using a semi-automated arraying
device (TMArrayer, Pathology Devices, Westminster, MD,
USA). As demonstrated previously, there was no selec-
tion bias regarding the distribution of clinicopatholog-
ical characteristics between the TMA cohort and the full
cohort [14].Immunohistochemistry and staining evaluation
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT-link system
(DAKO, Glostrup, Denmark) and then stained in an
Autostainer Plus (DAKO, Glostrup, Denmark). Immuno-
histochemical staining for SATB1 was performed using a
monoclonal anti-SATB1 antibody (Clone EPR3895, Epi-
tomics, Burlingame, CA, USA) diluted 1:100. The esti-
mated fraction of cells with nuclear SATB1 expression
was denoted as 0 (0-1%), 1 (2-25%), 2 (26-50%), 3 (51-
75%) and 4 (>75%). Nuclear intensity was denoted as
negative, weak, moderate or strong, with corresponding
scores from 0–3, referring to the predominant intensity.
A combined nuclear score (NS) was constructed by
multiplying fraction and intensity. SATB1 expression
was also evaluated in samples of normal colorectal
mucosa from the surgical resection margins (n = 20).
Stromal lymphocytes served as positive internal controls.
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assessed as previously described [4,18], whereby tumour
samples lacking nuclear staining of MLH1, PMS2, MSH2
or MSH6 were considered to have a positive MSI screen-
ing status. Hereafter, tumours with a positive MSI
screening status are referred to as MSI and tumours with
negative MSI screening status are referred to as MSS.
Immunohistochemical staining of beta-catenin was
performed with a monoclonal anti-beta-catenin anti-
body (# 610153 BD Pharmingen, San Diego, Ca, USA),
diluted 1:5000. The staining was evaluated as previously
described [19] whereby membranous staining was
denoted as 0 (present) or 1 (absent), cytoplasmic stain-
ing intensity as 0–2 and nuclear staining intensity as 0–
2. The total score ranging from 0 (corresponding to
membrane staining only, as in normal colonic mucosa)
to 5 (tumours with strong nuclear and cytoplasmic stain-
ing) was then divided into three categories; 1 = score 0–
1, 2 = score 2–3 and 3 = score 4–5). Sample IHC images
representing different beta-catenin grades are shown in
Additional file 1.
The immunohistochemical stainings was evaluated by
two independent observers (BN and KJ), who were
blinded to clinical and outcome data. Scoring differences
were discussed in order to reach consensus.
Antibody validation by ELISA and western blot analysis
Since SATB1 and SATB2 are very similar in sequence,
the specificity of the anti-SATB1 antibody was analysed
using ELISA and Western blot against purified recom-
binant SATB1 and SATB2 proteins. ELISA-plates
(Costar) were coated with purified recombinant MYK/
DDK-SATB1 produced in HEK293 cells (#TP300421,
Origene Technologies, Rockville, MD, USA) or full-
length SATB2 recombinant protein (#H00023314-P01,
Abnova, Taiwan) at 1 μg/ml per well and incubated
overnight at 4°C. Plates were blocked using 3% BSA in
PBS for 1 hr at RT. Anti-SATB1 antibody (Clone
EPR3895, Epitomics, Burlingame, CA, USA) was diluted
1:500 in 1% BSA in PBS and added to the wells. Follow-
ing incubation for 1 hr at RT, plates were washed 3
times with wash buffer (1xPBS/0,05% Tween 20) and an
HRP conjugated secondary antibody (#P0399, DakoCy-
tomation) diluted to 1:2000 was added and incubated for
1 hour at RT. Plates were washed as before, substrate
(Ready-to-use ABTS solution, Sigma Aldrich, #A3219)
was added and allowed to develop for 30 minutes at RT.
OD 405 was read on a microtiter plate reader.
For Western blot, 50 ng of purified recombinant
MYK/DDK-SATB1 produced in HEK293 cells (#TP300421,
Origene Technologies, Rockville, MD, USA) or 50 ng of a
full-length SATB2 recombinant protein (#H00023314-P01,
Abnova, Taiwan) were separated on precast 4–20% Criter-
ionTGX SDS- PAGE gradient gels (Bio-Rad Laboratories,Hercules, CA) under reducing conditions, followed by
blotting to PVDF membranes (Immobilon-P, Millipore),
according to the manufacturer's recommendations. Mem-
branes were blocked (5% dry milk, 0.5% Tween20,
1 ×TBS) for 45 min at RT prior to addition of antibody
(anti-SATB1, Clone EPR3895, Epitomics, Burlingame,
CA, USA, diluted 1:200; anti-SATB2, HPA029543, Atlas
Antibodies AB, Stockholm, Sweden, diluted 1:250). Fol-
lowing incubation for 1 h with the primary antibody, the
membranes were washed 4x5 min in 1xTBS with 0.1%
Tween20. An HRP-conjugated swine anti-rabbit antibody
(#P0399, DakoCytomation), diluted 1/3000 in blocking
buffer, was added to the membrane and incubated for 1 h
followed by a final round of washing. Detection was
carried out using Chemiluminescence HRP Substrate
(Immobilon) according to the manufacturer's instructions.
As demonstrated in Additional file 2 A and B, the
anti-SATB1 antibody binds specifically to SATB1 with
no discernable cross-reactivity to SATB2. Thus, the anti-
body is highly specific to SATB1 and does not cross-
react to SATB2, despite the extensive sequence similarity
shared by the two proteins.
Statistical analysis
Chi Square and Spearman’s correlation (R) tests were used
to explore the associations between SATB1 expression and
clinicopathological and investigative parameters. Kaplan-
Meier analysis and log rank test were used to illustrate
differences in cancer specific survival (CSS) and overall
survival (OS) according to three categories of SATB1
expression; negative (NS=0), intermediate (NS 1–3) and
high expression (NS >3), the latter including all tumours
with >75% positive nuclei or various fractions of
moderate-strong SATB1 staining. Cox regression pro-
portional hazards models were used for estimation of haz-
ard ratios (HRs) for death from CRC or overall causes
according to negative and positive SATB1 expression in
both uni- and multivariable analysis, adjusted for age
(>/<=75 years), gender, T-stage (I-II, III, IV), N-stage
(0,1,2), M-stage (0, 1), and differentiation grade (high-
intermediate vs low). A backward conditional selection
method was used for variable selection by the model. The
interaction between SATB1 expression and SATB2 expres-
sion was explored by a Cox proportional hazards model
including SATB1, SATB2 and an interaction variable. All
tests were two-sided. A p-value of≤ 0.05 was considered
significant. All statistical analyses were performed using
SPSS Statistics version 18 (SPSS Inc, Chicago, IL).
Results
Immunohistochemical expression of SATB1 in
colorectal cancer
Following antibody optimisation and staining, SATB1
expression was successfully annotated in 529 (95.0%)
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ple images of immunohistochemical SATB1 staining are
shown in Figure 1. SATB1 expression could be evaluated
in 16/20 (80%) samples of adjacent, benign-appearing
colorectal mucosa, of which 14 (87.5%) were denoted as
having negative expression (Figure 1A) and 2 (2.5%)Figure 1 Immunohistochemical images of SATB1 staining in colorecta
representing immunohistochemical expression of SATB1 staining in (A) nor
(B) negative through (C-D) weak intensity, (E-F) moderate intensity and (G-displayed weak expression in < 10% of cells. In the evalu-
ated CRC cohort, 307 (58.0%) of the tumours were
SATB1 negative (Figure 1B), and in the remaining
tumours, SATB1 was expressed in various fractions
and intensities (Additional file 3). In a small subset of
tumours, strong SATB1 expression was seen in the vastl cancer and adjacent colorectal mucosa. Images (20X )
mal colorectal mucosa and colorectal cancer, ranging from from
H) strong intensity in various fractions.
Table 1 Associations between SATB1 expression,
clinicopathological and molecular parameters in all
patients, and patients with colon and rectal cancer
(Continued)
SATB2 expression
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Notably, SATB2 was also abundantly expressed in all
these tumours, with a NS=12 in 15/18 cases and a NS=8
in 3 cases. There was no marked heterogeneity in SATB1
expression between duplicate cores.Table 1 Associations between SATB1 expression,
clinicopathological and molecular parameters in all
patients, and patients with colon and rectal cancer
SATB1 Expression Negative Intermediate High
n(%) 307(58.0) 126(23.8) 96(18.1) p-value}
(R)
Age
<=75 208(67.8) 86(68.3) 67(69.8) 0.736
>75 99(32.2) 40(31.7) 29(30.2) (−0.011)
Gender
Female 152(49.5) 71(56.3) 60(62.5) 0.020*
Male 155(50.5) 55(43.7) 36(37.5) (−0.097)
T-stage
1-2 54(18.2) 30(26.1) 24(25.8) 0.350
3 200(67.3) 67(58.3) 52(55.9) (−0.042)
4 43(14.5) 18(15.7) 17(18.3)
missing 10 11 3
N-Stage
0 165(58.1 64(59.8) 55(61.8) 0.719
1 74(26.1) 19(17.8) 21(23.6) (−0.007)
2 45(15.8) 24(22.4) 13(14.6)
missing 23 19 7
M-stage
0 252(83.4) 92(74.2) 85(89.5) 0.977
1 50(16.6) 32(25.8) 10(10.5) (0.036)
missing 5 2 1
Differentiation grade
Intermediate-High 233(77.2) 99(80.5) 70(75.3) 0.964
Low 69(22.8) 24(19.5) 23(24.7) (−0.009)
missing 5 3 3
Vascular invasion
No 89(47.8) 30(46.2) 29(52.7) 0.696
Yes 97(52.2) 35(53.8) 26(47.3) (−0.013)
missing 121 61 41
MSI screening status
MSS 227(78.3) 111(94.9) 87(92.6) <0.001**
MSI 63(21.7) 6(5.1) 7(7.4) (−0.212)
missing 17 11 2
Betacatenin grade
0 99(33.2 37(30.8) 16(16.8) <0.001**
1 105(35.2) 35(29.2) 26(27.4) (0.154)
2 94(31.5) 48(40.0) 53(55.8)
missing 9 6 1
negative 125(42.2) 22(11.2) 0(0.0) <0.001**
intermediate 133(44.9) 76(63.9) 41(43.2) (0.392)
high 38(12.8) 21(17.6) 54(56.8)
missing 11 7 1
Category denoted as negative refers to tumours with SATB1 nuclear score
(NS) = 0, intermediate to NS 1–3 and strong to NS > 3. } Chi square test for
linear trend. R = Spearman´s correlation coefficient.The categories marked as
not done and unknown were not included in the analysis. *Significant at the
0.05 level. ** Significant at the 0.01 level. N1 = 1-3 positive nodes, N2= > 4
positive nodes. MSS =Microsatellite stable, MSI =Microsatellite unstable.
Beta-catenin grade: 0 = score 0–1, 1 = score 2–3, 2 = score 4–5.Association between SATB1 expression,
clinicopathological and molecular characteristics
Next, we examined the relationship between SATB1
expression and established clinicopathological and inves-
tigative parameters. Three categories of staining were
compared, i.e. SATB1 negative tumours (NS= 0), an
intermediate group (NS = 1-3), and SATB1 high tumours
(NS > 3). In the full cohort, SATB1 expression was
significantly associated with female gender (p = 0.021),
but not with any other conventional clinicopathological
parameters (Table 1). A strong, signficant association
was however seen between SATB1 expression and
MSS tumours (p = <0.001), beta-catenin overexpression
(p = <0.001) and SATB2 expression (p = <0.001). In light
of the significant correlation between SATB1 and beta-
catenin overexpression, we also assessed the association
of SATB2 expression with beta-catenin grades, using the
same categories as in Table 1. In line with the findings
for SATB1, this revealed a strong positive correlation
between SATB2 expression and beta-catenin overexpres-
sion (p < 0.001). Similar correlations of SATB1 expres-
sion with clinicopathological and molecular parameters
were seen when the full range of nuclear scores was used
in the analyses (data not shown).
Associations between SATB1 expression and survival
Next, we examined the prognostic impact of SATB1
expression in strata of negative, intermediate and high
SATB1 expression (Figure 2). Kaplan Meier analysis
revealed no prognostic significance of SATB1 expression
for CSS, neither in the full cohort (Figure 2A), nor in separ-
ate analyses for colon and rectal cancers (data not shown).
Similar findings were seen for OS (data not shown).
The significant association of SATB1 expression with
MSI status, beta-catenin grades and SATB2 expression
led us to examine the modifying effect of these factors
on the prognostic value of SATB1 expression. While no
such effect was seen for MSI status and beta-catenin
Figure 2 Kaplan-Meier estimates of the prognostic impact of
SATB1 expression in all patients, and patients with SATB2
negative and positive tumours. Kaplan Meier analysis and log rank
test of colorectal cancer specific survival according to negative,
intermediate and high SATB1 expression in (A) all patients, (B)
patients with SATB2 negative and (C) patients with SATB2 positive
tumours. The categories of staining were determined according to
the nuclear score (NS), e.g. multiplier of fraction and intensity,
whereby negative SATB1 expression=NS 0, intermediate
expression=NS 1–3 and strong expression=NS >3.
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ciated with a shorter CSS in SATB2 negative tumours
(p = 0.001, Figure 2B), in contrast to SATB2 positive
tumours, where SATB1 was not significantly asso-
ciated with survival (Figure 2C). Notably, none of the
SATB2 negative tumours displayed high SATB1 staining
(Figure 3B). The adverse prognosis for SATB1 positive/
SATB2 negative tumours was confirmed in univariable
Cox regression analysis (HR= 2.63; 95% CI 1.46-4.71,
p = 0.001 for CSS and HR= 2.31; 95% CI 1.32-4.04,
p = 0.003 for OS), remaining significant in multivariable
analysis, adjusted for age, gender, TNM stage and differ-
entiation grade (HR= 2.07; 95% CI 1.06-4.05, p = 0.034
for CSS and HR= 2.05; 95% CI 1.09-3.88, p = 0.026 for
OS) (Table 2), with a significant interaction between
SATB1 and SATB2 expression (pinteraction =0.011 for CSS
and 0.015 for OS) (Table 2). The independent prognostic
value of SATB1 was lost when vascular invasion was
included in the multivariable analysis (data not shown).Figure 3 Kaplan-Meier estimates of the prognostic impact of
SATB1 expression in all patients, and patients with SATB2
negative and positive tumours. Kaplan–Meier estimates of colorectal
cancer-specific survival according to combinations of negative and
positive SATB1 and SATB2 expression. Log rank P-values correspond to
pairwise comparisons of tumours negative for both SATB1 and SATB2
with the other strata.
Table 2 Cox proportional hazards analysis of the prognostic interaction of SATB1 with SATB2 expression
Cancer specific survival Overall survival
HR(95%CI) p p† HR(95%CI) p p†
All SATB2 positive tumours univariable univariable
SATB1 neg 1,00 171(52) 1,00 171(67)
SATB1 pos 1.09(0.75-1.57) 0.649 192(64) 1.01(0.73-1.41) 0.932 192(77)
0.011 0.015
All SATB2 negative tumours univariable univariable
SATB1 neg 1,00 125(46) 1,00 125(56)
SATB1 pos 2.63(1.46-4.71) 0.001 22(15) 2.31(1.32-4.04) 0.003 22(16)
multivariable multivariable
SATB1 neg 1,00 115(40) 1,00 115(48)
SATB1 pos 2.07(1.06-4.05) 0.034 17(12) 2.05(1.09-3.88) 0.026 17(13)
Multivariable analysis included adjustment for age (>/<=75 years), gender, T-stage (I-II, III, IV), N-stage (0,1,2), M-stage (0, 1) and differentiation grade
(high-intermediate vs low). p†: P-value for term of interaction by Cox multivariate analysis including SATB1 expression, SATB2 expression, and a term
of interaction.
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to SATB1 expression (Figure 3).
Discussion
The results from this large, prospective cohort study of
colorectal cancer demonstrate that SATB1 is expressed
in a subset of colorectal carcinomas, and correlates with
beta-catenin overexpression, microsatellite stable tumours
and SATB2 expression. Furthermore, while not prognostic
in the full cohort, SATB1 expression was found to be a
factor of poor prognosis in SATB2 negative tumours.
Despite the positive correlation between SATB1 and
SATB2 expression in CRC, it is evident that the expres-
sion pattern of SATB1 in normal mucosa and CRC
differs from SATB2, which is abundantly expressed in a
tissue-specific manner in the mucosa of the lower gastro-
intestinal tract and in the vast majority of CRC [3,4]. Our
results demonstrate that normal colorectal mucosa is
more or less devoid of SATB1 expression, which is in line
with the study by Meng et al. [12]. Furthermore, the pro-
portion of cases with invasive CRC expressing SATB1 was
42% in our study, which is also in line with previous find-
ings by Meng et al. [12], although, in contrast to their
study, we found no significant association between SATB1
expression and unfavourable clinicopathological charac-
teristics. Moreover, in contrast to SATB2 [4], the value of
SATB1 expression as a predictor of response to adjuvant
chemotherapy was not evident.
The antibody used in this study has been validated as
being highly specific towards SATB1, and therefore, the
risk of a crossreactivity with SATB2 is negligible. This
is also supported by the observation that SATB1 was
absent in the vast majority of normal colorectal mucosa
samples, which is in stark contrast to the strong
and abundant expression of SATB2 in non-malignant
mucosa of the lower GI-tract [3,4]. Moreover, althoughthe small and quite distinct subset of 18 tumours with a
particularly high SATB1 expression (NS= 12) expressed
similarly high levels of SATB2, it must be emphasized that
the proportion of tumours with high (NS=12) SATB2 ex-
pression was considerably higher, and that the majority of
these expressed no or weak levels of SATB1.
The association between SATB1 expression and adverse
outcome in SATB2 negative tumours is of potential sig-
nificance, although based on a post-hoc analysis in a
rather small subgroup. This should be considered in
future mechanistic studies on the roles and potential
interaction of SATB1 and SATB2 in colorectal carcino-
genesis and progression, as well as in validatory studies
on human CRC samples. In light of the observed syner-
gism between SATB1 and SATB2 at the expression level,
their antagonistic impact on prognosis may seem con-
tradictory. Moreover, even if a significant prognostic
interaction was observed between SATB1 and SATB2,
the prognostic value of SATB2 did not differ by SATB1
expression, which would have been expected if the two
proteins were antagonistic. One, more simplistic, explan-
ation for this observation could be that the beneficial
prognostic value of SATB2, being expressed in the ma-
jority of CRC [3] overrules the potential tumour-
promoting effects of SATB1. Another explanation could
be that SATB1 and SATB2 exert synergistic effects in the
majority of CRC, as reflected in their positive interrela-
tionship, but that, in the absence of SATB2, SATB1 may
reprogramme the tumours towards a more malignant
phenotype. This hypothesis is partly substantiated by the
findings by Wang et al., where SATB1 expression was
shown to be down-regulated upon overexpression of
SATB2 in a metastatic subclone of the SW480 CRC cell
line, and up-regulated after siRNA-mediated silencing
of SATB2 in SW480 cells [5]. Moreover, antagonistic
activities of SATB1 and SATB2 have been observed in
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appear to regulate the balance of self-renewal versus dif-
ferentiation [20].
Similar to SATB2 [12], SATB1 expression was asso-
ciated with microsatellite stable tumours. As regards
SATB2, this finding is not unexpected, as an inverse
association with MSI has been observed for other
markers of colorectal lineage [21], but the role of SATB1
in this respect is less evident and should also be consid-
ered in future studies.
Important functions for SATB1 have been implicated
in several other cancer forms, and its prognostic value
seems to be cancer-type specific [22]. In an initial study
on breast cancer, SATB1 was demonstrated to act as a
genetic master switch towards a more aggressive tumour
behaviour, and moreover, high immunohistochemical
expression of SATB1 in tumours fom a large cohort of
breast cancer patients was an independent marker of
poor prognosis [8]. However, two follow-up studies
failed to confirm a role for SATB1 in malignant behav-
iour of breast cancer cells, and analysis of tumours from
several patient cohorts revealed no association between
high SATB1 mRNA expression and adverse outcome
[23,24]. Possibly, the prognostic value of SATB1 in
breast cancer may depend on hormone receptor status
[24-26]. In gastric cancer, SATB1 expression has been
reported to correlate with a more malignant phenotype
and poor prognosis whereas in squamous cell carcinoma
of the lung, downregulation of SATB1 was demonstrated
to be associated with an impaired survival [27].
Notably, observations of a prognostic disconcordance
between mRNA and protein levels of candidate biomar-
kers are not uncommon, and from a clinical viewpoint,
immunohistochemistry has several advantages compared
to gene expression analyses, since it allows for quantita-
tive assessment of proteins in a morphological context,
which might have important prognostic implications.
Moreover, SATB1 is not only expressed in tumour cells,
but also in stromal lymphocytes, and, importantly, the
prognostic impact was evident even at low levels of
expression, not least in the subgroup of SATB2 negative
tumours. These findings are consistent with the study by
Han et al., where the majority of the breast cancer sam-
ples were denoted as having weak immunohistochemical
expression of SATB1, which still had considerable prog-
nostic impact [8]. It should also be pointed out that in
the study by Meng et al., there was a significant correl-
ation of SATB1 mRNA levels and protein expression,
both of which were associated with unfavourable clinico-
pathological characteristics [12].
Conclusion
The results of this study demonstrate that SATB1
expression in colorectal cancer is significantly associatedwith beta-catenin overexpression, microsatellite stability
and SATB2 expression. Furthermore, while not prognos-
tic in unstratified analysis, SATB1 expression is shown
to be a factor of poor prognosis in SATB2 negative
tumours. Future studies are needed to elucidate the
potential mechanisms by which SATB1 affects colorectal
cancer progression, not least its potential synergistic or
antagonostic effects with SATB2.
Additional files
Additional file 1: Sample immunohistochemical images of
beta-catenin grades. Sample images of beta-catenin staining representing
(A) normal colorectal epithelial cells with intact membranous beta-catenin
expression, and colorectal cancers with (B) intact membranous expression
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nuclear and cytoplasmic expression (grade 3).
Additional file 2: Validation of the anti-SATB1 antibody. The
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An anti-SATB2 antibody was included as a control in the western blot
experiment, which shows that both antibodies are specific for their
respective proteins.
Additional file 3: Distribution of SATB1 staining in the full cohort.
Distribution of all nuclear scores (fraction x intensity) of SATB1 expression
in the full cohort. Percentage is shown on the y-axis and absolute
numbers above the bars.
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